Progress in diagnosis and treatment of hospital acquired pneumonia

SHI Yi

DOI: https://doi.org/10.3969/j.issn.1672-6170.2007.01.005

2007-01-01

Abstract:Mortality of hospital acquired pneumonia is quite high.This article emphatically recommends the conception,diagnosis and antibiotic treatment of hospital acquired pneumonia.

What problem does this paper attempt to address?

Advances in diagnosis and treatment of lung infection caused by gram-positive coccus

SHI Yi

2010-01-01

Medical Journal of Chinese People's Liberation Army

Abstract:The incidence of gram-positive coccus infection was keeping rising in recent years,with increase in hospital-and community-acquired pneumonia,as well as the incidence of infection caused by drug-resistant bacteria.Staphylococcus sp.,Streptococcus sp.and Enterococcus sp.were the most common pathogens inducing infection of the respiratory system,among which Streptococcus ranked the first.Streptococcus pneumoniae is still the most common pathogen causing respiratory infection.Recently,infection produced by penicillin-resistant strains of Streptococcus pneumoniae became more and more prevalent,leading to frequent failure in treatment.Regarding to Staphylococcus aureus,the methicillin-resistant strains (MRSA) account for approximately 60% of the pathogens inducing hospital-acquired infections,and what is worse,such a tendency is spreading to community,while the features of community-acquired MRSA infections (CA-MRSA) are very different from that of hospital-acquired MRSA infections (HA-MRSA).The purpose of present article is mainly to summarize the advances in diagnosis and treatment of pneumonia caused by Streptococcus pneumoniae and Staphylococcus aureus.
New progress in etiological diagnosis and treatment of mycoplasma pneumoniae infection

WANG Ying-shuo,CHEN Zhi-min

2013-01-01

Abstract:Mycoplasma pneumoniae( MP) is a frequent cause of community-acquired bacterial respiratory infections in children and adult. There are three kinds of diagnosis methods for MP infection: culture,serology and PCR assay. At the present,serology and PCR assay are the two main laboratory tests for MP infection. Tetracyclines,fluoroquinolones and macrolides are three main drugs for MP treatment in clinics. In recent years,it has been reported that some MP strains are acquired resistance to these antimicrobials.The strains with resistance to macrolides and fluoroquinolones have been reported in vitro. Macrolides-resistant isolates are significantly increasing in clinics. However,no clinical isolates resistant to fluoroquinolones have been reported in the literature.
The analysis and prevention of hospital acquired pneumonia in surgical intensive care unite

YE Xiang-hong,LI Wei-qin,WANG Xin-ying,LIU Di,JIANG Fang-zheng

2007-01-01

Abstract:Objecttive:The etiological characters of hospital acquired pneumonia(HAP)in the last two years were compared and the prevention methods of main infection routes were made to decrease the morbidity of HAP in surgical ICU. Methods:The patients were enrolled from Jan.2004 to Dec.2005:①artificial airway.②APACHEⅡ>12.③acute lung injury(ALI)、acute respiratory distress syndrome(ARDS).④chronic bronchitis、chronic obstructive pulmonary diseases(COPD).⑤hypoimmunity(CD4/CD8<0.9).The airway care was managed by the professional airway care nursers,the sputum was sampled and identified of bacteria and the clinical date of HAP patients was record. Results:The pathogenic bacteria were 263 strains,gram negative was at 59.61%,gram positive was at 28.9% and fungus was at 11.79 % from the samples of 79 HAP patients.The above three bacteria were pseuduomonas-aeruginosa(51)、baumanii(46)、staphylococcus aureus(41).MRSA was at 53.66 percent of staphylococcus aureus. Conclusion:The HAP is related to the artificial airway and mechanical ventilation in surgical postoperative patients and the first pathogenic bacteria is pseuduomonas-aeruginosa.According to the analysis of pathogenic bacteria,the prevention of several key steps and professional airway care could improve the outcome of HAP patients.
Progress in the Diagnosis and Treatment of Childhood Mycoplasma Pneumoniae Infections

A PUMAROLA,M BELTRAN,E TARDIO,M CRUZ

DOI: https://doi.org/10.3969/j.issn.1000-3606.2008.07.003

2008-01-01

Abstract:Mycoplasma pneumoniae(MP)remains to be an important pathogen of childhood community-acquired pneumonia,and also has close relationship to asthma exacerbation. There is a much higher incidence of MP infection in older children than younger children. The latter,although with a lower infection rate,usually show a more severe clinical picture,and is prone to have tachypnea and retractions. High fever and irritative cough are characteristics of MP infections in older children. Serological method is the standard one for diagnosing MP infection,while PCR is more suitable for early diagnosis of MP infection in younger and immunocompromised patients. Macrolide is still the drug of choice for treatment of childhood MP pneumonia,but how to manage the refractory MP pneumonia has become a big challenge to clinical researchers.
Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Shio-Shin Jean,Yin-Chun Chang,Wei-Cheng Lin,Wen-Sen Lee,Po-Ren Hsueh,Chin-Wan Hsu

DOI: https://doi.org/10.3390/jcm9010275

IF: 3.9

2020-01-19

Journal of Clinical Medicine

Abstract:Septicaemia likely results in high case-fatality rates in the present multidrug-resistant (MDR) era. Amongst them are hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), two frequent fatal septicaemic entities amongst hospitalised patients. We reviewed the PubMed database to identify the common organisms implicated in HAP/VAP, to explore the respective risk factors, and to find the appropriate antibiotic choice. Apart from methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, extended-spectrum β-lactamase-producing Enterobacteriaceae spp., MDR or extensively drug-resistant (XDR)-Acinetobacter baumannii complex spp., followed by Stenotrophomonas maltophilia, Chryseobacterium indologenes, and Elizabethkingia meningoseptica are ranked as the top Gram-negative bacteria (GNB) implicated in HAP/VAP. Carbapenem-resistant Enterobacteriaceae notably emerged as an important concern in HAP/VAP. The above-mentioned pathogens have respective risk factors involved in their acquisition. In the present XDR era, tigecycline, colistin, and ceftazidime-avibactam are antibiotics effective against the Klebsiella pneumoniae carbapenemase and oxacillinase producers amongst the Enterobacteriaceae isolates implicated in HAP/VAP. Antibiotic combination regimens are recommended in the treatment of MDR/XDR-P. aeruginosa or A. baumannii complex isolates. Some special patient populations need prolonged courses (>7-day) and/or a combination regimen of antibiotic therapy. Implementation of an antibiotic stewardship policy and the measures recommended by the United States (US) Institute for Healthcare were shown to decrease the incidence rates of HAP/VAP substantially.

medicine, general & internal
[New developments in the diagnosis and treatment of community-acquired pneumonia]

Tatiana Velasquez,Sofia El Maazi,Anne Bergeron,Davide Bosetti,Laurent Kaiser,Cédric Gillabert,Chloé Chevallier-Lugon,Bénédicte Jalbert

DOI: https://doi.org/10.53738/REVMED.2024.20.888.1714

2024-09-25

Abstract:Community acquired pneumonia is a well-known entity in internal medicine. It represents 1.2 cases per 1000 inhabitants every year, and up to 14 cases per 100 inhabitants in people older than 65 years old. Despite our exposition to the disease almost daily, it is still the leading cause of death related to an infection. In 2019, The American Thoracic Society proposed a revision of its guidelines, especially concerning the diagnosis and the treatment of community acquired pneumonia. It is the latest academic society revision. Further-more, the SARS-CoV-2 pandemia has extended our knowledge of pulmonary infection and brought an adaptation of our practice.
Chinese Guidelines For The Diagnosis And Treatment Of Hospital-Acquired Pneumonia And Ventilator-Associated Pneumonia In Adults (2018 Edition)

Yi Shi,Yi Huang,Tian-Tuo Zhang,Bin Cao,Hui Wang,Chao Zhuo,Feng Ye,Xin Su,Hong Fan,Jin-Fu Xu,Jing Zhang,Guo-Xiang Lai,Dan-Yang She,Xiang-Yan Zhang,Bei He,Li-Xian He,You-Ning Liu,Jie-Ming Qu

DOI: https://doi.org/10.21037/jtd.2019.06.09

2019-01-01

Journal of Thoracic Disease

Abstract:Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are the most common hospital-acquired infections in China. The difficulty in diagnosis and treatment of HAP/VAP leads to high mortality. In China, it has been nearly two decades since the initial “ Guideline for the Diagnosis and Treatment of Hospital-acquired Pneumonia ( draft )” was published in 1999 (1). Afterwards, a number of guidelines for HAP/VAP have been published or updated at home and abroad (2-10). The definitions of HAP/VAP have been changing as more and more relevant researches available highlighting greater details. Moreover, there are growing evidence in the epidemiology, etiology, clinical diagnosis and treatment of HAP/VAP, especially the accumulating evidence from the researches in China, which shows that the distribution and antibiotic resistance rate of HAP/VAP pathogens in China are largely different from the data reported in other countries. Therefore, it is necessary to amend the initial guideline in 1999 accordingly in order to better guide clinical practice.
A Multicenter Clinical Trial on the Efficacy and Safety of Piperacillin/tazobactam for the Treatment of Patients with Hospital Acquired Pneumonia: Treatment of Hospital Acquired Pneumonia Forum in Huadong Area.

周新,万欢英,朱惠莉,施毅,林章树,蒋捍东,周建英,刘荣玉

DOI: https://doi.org/10.3969/j.issn.1671-6205.2009.01.006

2009-01-01

Abstract:Objective To evaluate the clinical efficacy and safety of piperacillin/tazobactam in the treatment of hospital acquired pneumonia(HAP).Methods A multicenter,open-labeled,non-comparative clinical trial was conducted.Patients with HAP were administered intravenously with piperacillin/tazobactam(4.5 g) every 8 h for 7-14 days.Results A total of 250 patients were enrolled in this study and 246 subjects were clinical valuable.At the end point,the clinical efficacy rate was 81.7%(201/246) and the bacterial eradication rate was 74.1%(83/112).The rate of drug related adverse events was 2.8%(7/250),in which 4 cases had clinical significance(rash,dyspnea,injection site pain and diarrhea,respectively) and 3 cases had abnormal laboratory findings(hepatic dysfuction,eosinophilia and so on).All events were mild and transient.ConclusionsPiperacillin/tazobactam is effective and safe in the treatment of HAP,therefore,it is recommended as one of the first-line antibiotics to treat the patients with HAP.
The Clinical Feature and Countermeasures of Hospital-Acquired Pneumonia in Non-Surgical Treatment Elderly Inpatients with Lung Cancer

HUANG Hu-wei,ZHOU Jian-ying

DOI: https://doi.org/10.13381/j.cnki.cjm.2009.10.029

2009-01-01

Abstract:Objective To analyze the clinical feature and treatment strategy of Hospital-acquired pneumonia (HAP) in old age patients with lung cancer. Method 275 cases of HAP in non-surgically treated elderly inpatients with lung cancer during January 2006 to December 2008 were included and analyzed retrospectively. Result Among these patients, 165 cases occurred Central-type lung cancer, squamous cell carcinoma were prone to develop HAP; HAP caused by gram-negative bacteria was significantly higher than that caused by gram-positive bacteria and fungi; HAP infection rate in radiotherapy plus chemotherapy group was higher than that in chemotherapy or radiotherapy alone group; Along with the decrease of neutrophilic leukocyte, the infection rate was significantly higher, especially when the neutrophilic leukocyte < 1.0 × 10~9/L. Conclusion According to the clinical feature of HAP in non-surgically treated elderly inpatients with lung cancer, the prevention of HAP should be a fundamental measure, and treatment should be given in time once the infection occurs.
Management of pneumonia in critically ill patients

Catia Cillóniz,Antoni Torres,Michael S Niederman,Catia Cilloniz

DOI: https://doi.org/10.1136/bmj-2021-065871

2021-12-07

The BMJ

Abstract:Severe pneumonia is associated with high mortality (short and long term), as well as pulmonary and extrapulmonary complications. Appropriate diagnosis and early initiation of adequate antimicrobial treatment for severe pneumonia are crucial in improving survival among critically ill patients. Identifying the underlying causative pathogen is also critical for antimicrobial stewardship. However, establishing an etiological diagnosis is challenging in most patients, especially in those with chronic underlying disease; those who received previous antibiotic treatment; and those treated with mechanical ventilation. Furthermore, as antimicrobial therapy must be empiric, national and international guidelines recommend initial antimicrobial treatment according to the location's epidemiology; for patients admitted to the intensive care unit, specific recommendations on disease management are available. Adherence to pneumonia guidelines is associated with better outcomes in severe pneumonia. Yet, the continuing and necessary research on severe pneumonia is expansive, inviting different perspectives on host immunological responses, assessment of illness severity, microbial causes, risk factors for multidrug resistant pathogens, diagnostic tests, and therapeutic options.
[Adult Hospital Acquired Pneumonia: a Multicenter Study on Microbiology and Clinical Characteristics of Patients from 9 Chinese Cities].

You-ning Liu,Bin Cao,Hui Wang,Liang-an Chen,Dan-yang She,Tie-mei Zhao,Zhi-xin Liang,Tie-ying Sun,Yan-ming Li,Zhao-hui Tong,Zhen Wang,Bei He,Wei Yang,Jie-ming Qu,Xiang-yang Li,Rong-chang Chen,Feng Ye,Jian Kang,Er-ran Li,Ping Chen,Yan Zheng,Zhong-sen Ma,Jin Ren,Yi Shi,Wen-kui Sun,Yu-lin Feng,Hong Fan,Shu-juan Jiang,Song Zhang,Sheng-dao Xiong,Peng Zuo,Zhan-wei Wang

DOI: https://doi.org/10.3760/cma.j.issn.1001-0939.2012.10.009

2012-01-01

Abstract:OBJECTIVE:To investigate the etiology and clinical characteristics of hospital-acquired pneumonia (HAP) in China and to provide evidence for appropriate therapy.METHODS:We performed a prospective multicenter study in 13 Chinese urban tertiary hospitals. All HAP cases diagnosed at respiratory general ward and respiratory intensive care unit (RICU) from August 2008 to December 2010 were studied. Epidemiological data, etiology and clinical characteristics of enrolled patients were collected. Sputum or tracheal aspirate and blood cultures, Legionella antibodies and Streptococcus pneumoniae urinary antigen tests were performed. Bacteria to antimicrobial susceptibility test was performed.RESULTS:A total of 610 cases of HAP were diagnosed during the study, with an overall incidence of 1.4% among 42 877 hospitalized patients, while the incidence was 0.9% (362/41 261) in respiratory general ward and 15.4% (248/1616) in RICU. 93.9% (573 cases) of patients had at least one underlying disease, and 91.0% (555 cases) had exposure to at least one antimicrobial agent within 90 days prior to HAP diagnosis. Pathogens were identified in 487 patients, with Acinetobacter baumannii [30.0% (183/610)], Pseudomonas aeruginosa [22.0% (134/610)], Staphylococcus aureus [13.4% (82/610)] and Klebsiella pneumonia [9.7% (59/610)] being the most common pathogens. Eighteen patients (3.0%) had infection with fastidious bacteria. A. baumannii and S. aureus were the more frequent pathogens in the ventilator-associated pneumonia (VAP) cases [50.5% (97/192) and 21.4% (41/192)] as compared to non-VAP cases [20.6% (86/418) and 9.8% (41/418), P < 0.01]. A. baumannii and S. aureus were also frequent pathogens in cases with a score of more than 20 by the acute physiology and chronic health evaluation II (APACHEII) scoring [45.7% (69/151) and 20.5% (31/151)], as compared to cases with a score of less than 20 of APACHE II [24.8% (114/459) and 11.1% (51/459), P < 0.01]. A. baumannii showed high resistance rates to carbapenems [more than 70% (109/142)], and the susceptibility to cefoperazone/sulbactam, polymyxin B and tigecycline were 40.8% (58/142), 99.3% (141/142) and 95.8% (136/142) respectively. Resistance rates of P. aeruginosa to meropenem and imipenem were 48.8% (40/82) and 70.7% (58/82) respectively. Methicillin-resistant S. aureus (MRSA) accounted for 87.8% (43/49) in all strains of S. aureus. Mortality rate of VAP cases was 34.5% (61/177), significantly more than that of HAP patients [22.3% (135/605), P < 0.05]. The average hospital stay of patients with HAP was (23.8 ± 20.5) days, significantly more than that of the average for inpatients [(13.2 ± 13.6) days, P < 0.01] during the study period. Mean costs of HAP were (108 950 ± 116 608) yuan, significantly higher than the average hospital costs of respiratory inpatients (17 999 ± 33 364) yuan.CONCLUSIONS:Among Chinese patients hospitalized in urban tertiary medical centers, HAP incidence and mortality rate were high, which increased the patients' hospital stay and the medical costs. Common pathogens were A. baumannii, P. aeruginosa, S. aureus and K. pneumonia. The common bacteria of HAP in China showed high resistance rates to antibiotics.
Hospital-associated Pneumonia in a Respiratory Intensive Care Unit: Clinical Analysis

LU Xin,SUN Wenkui,XU Jin,LI Miaomiao,SU Xin,ZHAO Beilei,SUN Huiming,SHI Yi

DOI: https://doi.org/10.3969/j.issn.1009-7708.2012.05.006

2012-01-01

Abstract:Objective To investigate the incidence,risk factors,pathogens and outcomes of hospital-associated pneumonia (HAP) in a respiratory intensive care unit(RICU).Methods The clinical data of HAP patients in a RICU were reviewed retrospectively from August 2008 to August 2010.Results The incidence rate of HAP was 17.3%in the RICU.Risk factors for HAP included age,long ICU stay,underlying diseases such as chronic obstructive pulmonary disease,cerebrovascular disease, diabetes mellitus,malignant tumors,invasive procedures,placement of catheter,use of proton pump inhibitor and multiple organ dysfunction syndrome.The main pathogens of HAP were Acinetobacter baumannii,Pseudomonas aeruginosa and Staphylococcus aureus.The overall mortality was 42%.About 54%of the HAP responded to the antimicrobial therapy.Conclusions HAP is a serious problem in RICU.The key to successful treatment of HAP is dependent on active prevention measures targeting high-risk groups;management of underlying diseases,control of risk factors,environment optimization and antibiotic combination therapy.
The importance of atypical pathogens to the guidelines of community acquired pneumonia in the world

SHI Yi

2009-01-01

Abstract:Atypical pathogens are very common in community-acquired pneumonia(CAP) with the morbidity of about 22%(20%～28%).Therefore,CAP guidelines around the world usually emphasize the importance of atypical pathogens.The diagnosis tests are also listed in the guidelines,but only applied among inpatients.Japanese Respiratory Society recommended the diagnosis criteria of atypical pneumonia based on the clinical characteristics for the first time in the world.All guidelines recommended that empirical antibiotic therapy should cover those atypical pathogens when Mycoplasma pneumoniae,Chlamydia pneumonia or legionella pneumophilia infection are possibly exist.Antibiotic therapy against Mycoplasma pneumoniaen and Chlamydia pneumonia should be considered among outpatients and inpatients as well as anti-legionella pneumophilia therapy in severe patients in ICU.The recommended regimen is beta-lactam antibiotics combined with macrolides or fluoroquinolones alone.
Current Concepts in Community and Ventilator Associated Lower Respiratory Tract Infections in ICU Patients

Ignacio Martin-Loeches

DOI: https://doi.org/10.3390/antibiotics9070380

2020-07-05

Antibiotics

Abstract:It is widely known that pneumonia (either community acquired or hospital acquired, as like ventilator associated pneumonia (VAP)), is the most frequent type of severe infection and continues to pose a significant burden on healthcare services worldwide. Despite new diagnostic developments, most pneumonia cases continue to be difficult to diagnose clinically, partly due to acquired antibiotic resistance and the lack of a ‘gold standard’ method of diagnosis. In other words, the lack of a rapid, accurate diagnostic test, as well as the uncertainty of the initial etiologic diagnosis and the risk stratification, results in empirical antibiotic treatments. There are significant changes in the aetiology of patients with ventilator associated lower respiratory tract infections (VA-LRTI), which are characterised by a higher incidence of multi drug resistant organisms. Evidence suggests that when patients with VA-LRTI develop organ failure, the associated mortality can be exceptionally high with frequent complications, including acute respiratory distress syndrome, acute kidney injury, and septic shock. Appropriate antibiotic treatments must consider that the present cardiovascular failure seen in patients has a different association with the patient’s mortality. Unlike patients with less severe clinical presentations, who have a higher chance of survival when the appropriate antibiotics are administered promptly, for patients with a severe subtype of the disease, the appropriateness of antibiotic treatment will impact the patient’s outcome to a lesser extent. The present review highlights certain factors detectable at the time of admission that could indicate patients who are at a high risk of bacteraemia and who, therefore, merit more intense therapy and stratified care.
Epidemiological study on hospital-acquired pneumonia of Acinetobacter baumannii

Yi-lun WANG,Bi-jie HU,Hong-you CHEN,Xiao-dong GAO,Yu-zhang SHAN,Qing-feng SHI,Chun-mei ZHOU

DOI: https://doi.org/10.11816/cn.ni.2017-170460

2017-01-01

Abstract:OBJECTIVE To investigate the molecular epidemiological characteristics, antibiotic resistance and possible routes of transmission of hospital-acquired pneumonia caused by Acinetobacter baumannii in the hospital, so as to provide references for clinical treatment.METHODS Clinical data of patients were collected using the hospital medical records system between Jul.2013 and Jun.2015.Isolates were typed by pulsed-field gel electrophoresis (PFGE) and the microorganism susceptibility was tested using Kirby-Bauer (K-B) method.RESULTS The mortality of the 114 patients with hospital-acquired pneumonia due to A.baumannii was 43.9%.Totally 17 banding patterns (A-Q) were identified in 114 isolates, including 99 epidemic strains (A-E) and 15 sporadic isolates (F-Q).Most of the strains were isolated from intensive care unit (ICU).Drug sensitivity test results showed that, all epidemic strains were multi-resistant A.baumannii(MDRAB), of which 96% were the carbapenem-resistant A.baumannii (CRAB).The resistance rates to cefperazone/sulbactam and tigecycline were low.CONCLUSION Multiple epidemic clusters existed in the hospital with high drug resistance to most kinds of antibiotics.Patient-to-patient transmission and environmental transmission may be the main route.Therefore, intensive infection control measures should be taken to prevent the transmission of the pathogen due to the poor prognosis of the patients.
Hospital Acquired Infections and Non-Hospital Acquired Infections in the Department of Critical Care Medicine

SHI Zhan,CHANG Zhigang

DOI: https://doi.org/10.12290/xhyxzz.2024-0119

2024-01-01

Abstract:Patients with infections in the department of critical care medicine have complex sources and diverse sites of infection, which may be associated with multiple pathogenic bacteria and have a high rate of drug resistance, posing a significant challenge to clinical diagnosis and treatment. Infections in the department of critical care medicine can be divided into two types: hospital acquired infections and non-hospital acquired infections, with significant differences in clinical characteristics between the two. This article discusses the relevant concepts, risk factors, pathogenesis, and common characteristics of severe infections such as bloodstream infections, pulmonary infections, intra-abdominal infections, and intracranial infections, as well as diagnostic and treatment plans and prevention and control strategies from the perspectives of hospital acquired and non-hospital acquired infections, aiming to provide valuable guidance for the clinical management of critically ill patients.
Current status of diagnosis and treatment of viral pneumonia in adults

Wen XI,Zhancheng GAO

DOI: https://doi.org/10.7507/1002-0179.201712026

2018-01-01

Abstract:Respiratory viruses are important pathogens responsible for community-and hospital-acquired pneumonia in adults.Outbreaks of highly pathogenic viruses in recent years have made us aware of the difficulty and importance of diagnosis and treatment of viral pneumonia.This review summarized the current status of diagnosis and treatment of viral pneumonia in adults so as to improve our understanding of it.
Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review

Don Davis,Jainisha Thadhani,Vatsalya Choudhary,Reem Nausheem,Cristhian R Vallejo-Zambrano,Bushra Mohammad Arifuddin,Mujahaith Ali,Bryan J Carson,Fnu Kanwal,Lavanya Nagarajan

DOI: https://doi.org/10.7759/cureus.46893

2023-10-12

Cureus

Abstract:Pneumonia, classified as a lower respiratory tract illness, affects different parts of the bronchial system as well as alveoli and can present with varying severities depending on co-morbidities and causative pathogens. It can be broadly classified using the setting in which it was acquired, namely the community or hospital setting, the former being more common and spreading through person-to-person droplet transmission. Community-acquired pneumonia (CAP) is currently the fourth leading cause of death worldwide, and its high mortality makes continual insight into the management of the condition worthwhile. This review explores the literature specifically for severe CAP (sCAP) and delves into the diagnosis, various modalities of treatment, and management of the condition. This condition can be defined as pneumonia requiring mechanical ventilation in the ICU and/or presenting with sepsis and organ failure due to pneumonia. The disease process is characterized by inflammation of the lung parenchyma, initiated by a combination of pathogens and lowered local defenses. Acute diagnosis of the condition is vital in reducing negative patient outcomes, namely through clinical presentation, blood/sputum cultures, imaging modalities such as computed tomography scan, and inflammatory markers, identifying common causative pathogens such as Streptococcus pneumoniae, rhinovirus, Legionella, and viral influenza. Pathogens such as Escherichia coli should also be investigated in patients with chronic obstructive pulmonary disease. The mainstay of treating sCAP includes rapid ICU admission once a diagnosis has been confirmed, initiating sepsis protocol, and treatment with combined empiric antibiotic regimens consisting of beta-lactams and macrolides. Corticosteroid use alongside antibiotics shows promise in reducing inflammation, but its use has to be judged on a case-by-case basis. New drugs such as omadacycline, delafloxacin, and zabofloxacin have shown valid evidence for the treatment of resistant causative organisms. The main guidelines for preventing sCAP include maintaining a healthy lifestyle, and annual pneumococcal and influenza vaccines are recommended for the most vulnerable patient groups, such as those with COPD and immunosuppression.
Epidemiology, microbiology and treatment implications in adult patients hospitalized with pneumonia in different regions of China: a retrospective study.

Fan Liu,Zehuai Wen,Jia Wei,Huiling Xue,Yunqin Chen,Weiguo Gao,David Melnick,Jesus Gonzalez,Judith Hackett,Xiaoyan Li,Shizhou Deng,Zhaolong Cao

DOI: https://doi.org/10.21037/jtd.2017.09.18

2017-01-01

Journal of Thoracic Disease

Abstract:Background: Data describing epidemiology, clinical outcomes and treatment patterns, of hospitalised patients with pneumonia in China are limited. We aimed to describe such information among adult pneumonia patients in southern and northern China. Methods: We retrospectively reviewed electronic medical records of pneumonia patients aged >= 18 years, hospitalized between 2008 and 2013 at Guangdong Provincial Hospital of Chinese Medicine (n=3,636), southern China, and between 2010 and 2014 at Peking University People's Hospital, Beijing (n=1,689), northern China, in order to collect data on patient demographics, microbiology, clinical outcomes and treatment and resistance patterns. Results: The mean (SD) age of patients was 60.0 (21.4) and 64.4 (18.4) years in Guangdong and Beijing, respectively. Mean length of hospital stay was 12.1 and 20.8 days, and overall mortality was 2.9% and 8.0%, respectively. Gram-negative bacilli were most frequently isolated, predominantly Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa. Infection with these bacteria was associated with unfavourable clinical outcomes, and the antibiotic resistance among these bacteria increased between 2008-2010 and 2011-2013 in both regions of China. The treatment and choice of antibiotics slightly varied between the two regions based on the susceptible pathogens identified among their populations. Conclusions: Of the pathogens identified, Staphylococcus aureus infection (particularly the methicillinresistant S. aureus) was associated with poor clinical outcomes; however antibiotic resistance among S. aureus generally decreased during the study data collection periods. Also, disease severity was greater in Beijing as compared with Guangdong, and this may be associated with higher microbiological diagnosis rate and higher frequency of initial antibiotic modification among Beijing populations.
Hospital-acquired bacterial pneumonia in critically ill patients: from research to clinical practice

Pompeo Costantino Kouroupis,Niall O’Rourke,Sinead Kelly,Myles McKittrick,Elne Noppe,Luis F. Reyes,Alejandro Rodriguez,Ignacio Martin-Loeches

DOI: https://doi.org/10.1080/14787210.2024.2354828

2024-05-22

Expert Review of Anti-infective Therapy

Abstract:Introduction Hospital-acquired pneumonia (HAP) represents a significant cause of mortality among critically ill patients admitted to Intensive Care Units (ICUs). Timely and precise diagnosis is imperative to enhance therapeutic efficacy and patient outcomes. However, the diagnostic process is challenged by test limitations and a wide-ranging list of differential diagnoses, particularly in patients exhibiting escalating oxygen requirements, leukocytosis, and increased secretions.

pharmacology & pharmacy,infectious diseases,microbiology

Progress in diagnosis and treatment of hospital acquired pneumonia

Advances in diagnosis and treatment of lung infection caused by gram-positive coccus

New progress in etiological diagnosis and treatment of mycoplasma pneumoniae infection

The analysis and prevention of hospital acquired pneumonia in surgical intensive care unite

Progress in the Diagnosis and Treatment of Childhood Mycoplasma Pneumoniae Infections

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

[New developments in the diagnosis and treatment of community-acquired pneumonia]

Chinese Guidelines For The Diagnosis And Treatment Of Hospital-Acquired Pneumonia And Ventilator-Associated Pneumonia In Adults (2018 Edition)

A Multicenter Clinical Trial on the Efficacy and Safety of Piperacillin/tazobactam for the Treatment of Patients with Hospital Acquired Pneumonia: Treatment of Hospital Acquired Pneumonia Forum in Huadong Area.

The Clinical Feature and Countermeasures of Hospital-Acquired Pneumonia in Non-Surgical Treatment Elderly Inpatients with Lung Cancer

Management of pneumonia in critically ill patients

[Adult Hospital Acquired Pneumonia: a Multicenter Study on Microbiology and Clinical Characteristics of Patients from 9 Chinese Cities].

Hospital-associated Pneumonia in a Respiratory Intensive Care Unit: Clinical Analysis

The importance of atypical pathogens to the guidelines of community acquired pneumonia in the world

Current Concepts in Community and Ventilator Associated Lower Respiratory Tract Infections in ICU Patients

Epidemiological study on hospital-acquired pneumonia of Acinetobacter baumannii

Hospital Acquired Infections and Non-Hospital Acquired Infections in the Department of Critical Care Medicine

Current status of diagnosis and treatment of viral pneumonia in adults

Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review

Epidemiology, microbiology and treatment implications in adult patients hospitalized with pneumonia in different regions of China: a retrospective study.

Hospital-acquired bacterial pneumonia in critically ill patients: from research to clinical practice